The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more ...
Eli Lilly & Co. closed $177.18 short of its 52-week high ($972.53), which the company reached on August 22nd. Supported by ...
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...
American drugmaker Eli Lilly and Company's India unit is set to see a leadership change with managing director ...
Zacks.com on MSN1d
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItEli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment ...
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback